Camila S. Freitas

Belo Horizonte, MG, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model.

Recombinant vaccine plus anti-parasitic agent in an immunotherapeutic schedules induce partial regression of tegumentary leishmaniasis in a murine model.

Journal: Vaccine

Published: June 03, 2026

Improved detection of paucibacillary and multibacillary leprosy using a novel recombinant chimeric protein.

Improved detection of paucibacillary and multibacillary leprosy using a novel recombinant chimeric protein.

Journal: Journal of immunological methods

Published: March 20, 2026

Comparison of a recombinant endonuclease III protein and its synthetic peptides in ELISA for the diagnosis of tegumentary leishmaniasis using human serum and urine samples: A preliminary study.

Comparison of a recombinant endonuclease III protein and its synthetic peptides in ELISA for the diagnosis of tegumentary leishmaniasis using human serum and urine samples: A preliminary study.

Journal: PLoS neglected tropical diseases

Published: February 02, 2026

Differential lethal action of octyl and oct-4E-enyl p-nitrobenzoates in Leishmania spp. - a mechanistic study.

Differential lethal action of octyl and oct-4E-enyl p-nitrobenzoates in Leishmania spp. - a mechanistic study.

Journal: Chemico-biological interactions

Published: January 12, 2026

Diagnostic evaluation of a novel recombinant multi-epitope protein for paucibacillary and multibacillary leprosy.

Diagnostic evaluation of a novel recombinant multi-epitope protein for paucibacillary and multibacillary leprosy.

Journal: Tuberculosis (Edinburgh, Scotland)

Published: November 07, 2025

Brain Involvement in Leishmaniasis.

Brain Involvement in Leishmaniasis.

Journal: Cell biochemistry and function

Published: October 24, 2025

Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis.

Immunotherapeutics Combining a Recombinant Chimeric Protein, Monophosphoryl Lipid A, and Miltefosine Against Visceral Leishmaniasis.

Journal: Pathogens (Basel, Switzerland)

Published: September 22, 2025

Recombinant small myristoylated protein-3 and synthetic peptide as diagnostic and prognostic biomarkers for tegumentary leishmaniasis.

Recombinant small myristoylated protein-3 and synthetic peptide as diagnostic and prognostic biomarkers for tegumentary leishmaniasis.

Journal: Parasitology international

Published: September 17, 2025

Polymeric micelles loaded with a 1,2,3-triazolium derivative: a promising strategy against tegumentary leishmaniasis.

Polymeric micelles loaded with a 1,2,3-triazolium derivative: a promising strategy against tegumentary leishmaniasis.

Journal: Acta tropica

Published: May 23, 2025

Urine- and serum-based ELISA using a new recombinant chimeric protein to diagnose tegumentary and visceral leishmaniasis: a preliminary study.

Urine- and serum-based ELISA using a new recombinant chimeric protein to diagnose tegumentary and visceral leishmaniasis: a preliminary study.

Journal: Experimental parasitology

Published: February 07, 2025

Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis.

Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis.

Journal: Parasitology

Published: November 28, 2024

Urine-based ELISA using a recombinant chimeric protein for the diagnosis of paucibacillary and multibacillary leprosy.

Urine-based ELISA using a recombinant chimeric protein for the diagnosis of paucibacillary and multibacillary leprosy.

Journal: Tuberculosis (Edinburgh, Scotland)

Published: October 31, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026